Nicox attends 2012 AAO Meeting in Chicago

Nicox attends 2012 AAO Meeting in Chicago
...................................

November 9, 2012.
 
Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX) is attending the American Academy of Ophthalmology (AAO) & Asia Pacific Academy of Ophthalmology (APAO) 2012 Joint Meeting, taking place from November 10 to 13 in Chicago, Illinois, United States (US). Nicox can be found at booth number 2735.

Nicox's US operational team, including Jerry St. Peter, Executive Vice President (EVP) and General Manager of Nicox Inc, will present AdenoPlus(TM), a rapid point-of-care diagnostic test that aids in the differential diagnosis of acute conjunctivitis. AdenoPlus(TM) was launched by Nicox in the US in October 2012 (see Nicox press release dated October 22, 2012).

Michele Garufi, Chairman and CEO, Gavin Spencer, EVP Corporate Development and Philippe Masquida, EVP, Managing Director of European & International Operations will also attend the meeting.

Nicox's goal is to become a new international player in the ophthalmic market by building a diversified portfolio of innovative therapies and diagnostic tools.
...................................

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new international player in the ophthalmic market by building a diversified portfolio of innovative therapies and diagnostic tools. With a heritage of scientific, business development and commercial expertise, strengthened by internal research capabilities, Nicox is focused on developing and marketing novel pharmaceuticals and diagnostics that can help people to enhance their sight. In the United States, Nicox markets AdenoPlus(TM), a test for the differential diagnosis of acute conjunctivitis in-licensed from RPS®, to eyecare practitioners.

The Company's pipeline includes BOL-303259-X, a novel drug-candidate based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, developed in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donating compounds are under development in non-ophthalmic indications, notably through partners, including Merck (known as MSD outside the United States and Canada) and Ferrer.

Nicox S.A. is headquartered in France and is listed on Euronext Paris (Compartment C: Small Caps). For more information
please visit www.nicox.com.

...................................

Contacts
Nicox	Gavin Spencer | Executive Vice President Corporate Development
	Tel +33 (0)4 97 24 53 00 | communications@nicox.com
	www.nicox.com
Media Relations	FTI Consulting
Europe	Jonathan Birt | D+44 (0)20 7269 7205 | M +44 (0) 7515 597 858
	Jonathan.Birt@fticonsulting.com
	Stephanie Cuthbert | D +44 (0)20 3077 0458 | M +44 (0) 7843 080947
	Stephanie.Cuthbert@fticonsulting.com